Open Government Portal
Found 10 records similar to SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2)
This biosafety advisory is being provided by the Public Health Agency of Canada (PHAC) to assist clinical, diagnostic, and research laboratories in implementing proper biosafety procedures to safely handle samples that may contain SARS-CoV-2. This biosafety advisory also aims to support local risk assessments (LRAs) of facilities where whole live SARS-CoV-2 or purified or chemically synthesized full length SARS-CoV-2 RNA are handled. SARS-CoV-2 is the virus responsible for the COVID-19 pandemic, which began in December 2019. This biosafety advisory is based on the scientific evidence available as of November 2, 2021, and is subject to review and revisions as new information becomes available.
Variant strains of SARS-CoV-2 are emerging that may affect the level of protection provided by currently authorized COVID-19 vaccines. As a result, manufacturers are adapting authorized COVID-19 vaccines to provide protection against infection and disease caused by virus variants.
We present the most up-to-date data on SARS-CoV-2 antibody timelines, including the longevity of antibodies, and the production and detection of neutralizing antibodies and provide practical guidance for clinical microbiology laboratories to both verify commercial serology assays and choose appropriate testing algorithms for their local populations.
This Points to Consider document lays out a regulatory approach for updating authorised coronavirus vaccines should mutations at any time make them less efficacious due to insufficient cross-reactivity.
Simple mathematical modelling approaches to assessing the transmission risk of SARS-CoV-2 at gatherings
The Public Health Agency of Canada, in collaboration with provincial and territorial public health authorities, established the Canadian SARS-CoV-2 Variant Surveillance Group (CSVSG) to monitor and assess the impact of variants of SARS-CoV-2 on viral transmissibility, disease severity, and efficacy of vaccines, therapeutics, and diagnostics. The CSVSG has developed national definitions, classifications, and public health actions for SARS-CoV-2 Variants of Interest (VOI) and Variants of Concern (VOC).
Some Canadians are at risk of developing severe complications from an illness due to underlying medical conditions and age. If you are at risk for complications, you can take action to reduce your risk of getting sick from COVID-19.
While diseases can make anyone sick, some Canadians are more at risk of developing severe complications from an illness due to underlying medical conditions and age. If you are at risk for complications, you can take action to reduce your risk of getting sick from COVID-19.
The World Health Organization (WHO) refers to symptoms lasting for weeks or months after a COVID-19 infection as post COVID-19 condition. Some studies have reported later symptoms in patients with a severe COVID-19 infection. For example, those who were hospitalized or needed intensive care during recovery. However, post COVID-19 condition may also occur for people with mild or asymptomatic infection who were asked to isolate at home during the infectious phase.
This guidance has been adapted for Canadian use from the WHO document entitled "Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected – Interim guidance - 13 March 2020". This guidance is informed by currently available scientific evidence and expert opinion, and is subject to change as new information becomes available.